1 |
DINARDO C D, ERBA H P, FREEMAN S D, et al. Acute myeloid leukaemia[J].Lancet,2023,401(10393): 2073-2086.
|
2 |
SHIMONY S, STAHL M, STONE R M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2023, 98(3): 502-526.
|
3 |
BHANSALI R S, PRATZ K W, LAI C. Recent advances in targeted therapies in acute myeloid leukemia[J]. J Hematol Oncol, 2023, 16(1): 29.
|
4 |
HASHEMINEZHAD S H, BOOZARI M, IRANSHAHI M, et al. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins[J]. Phytother Res,2022,36(1): 112-146.
|
5 |
DAS S, SHUKLA N, SINGH S S, et al. Mechanism of interaction between autophagy and apoptosis in cancer [J]. Apoptosis, 2021, 26(9-10): 512-533.
|
6 |
SAHASHI H, KATO A, YOSHIDA M, et al. Urolithin A targets the AKT/WNK1 axis to induce autophagy and exert anti-tumor effects in cholangiocarcinoma[J]. Front Oncol, 2022, 12: 963314.
|
7 |
ALZAHRANI A M, SHAIT MOHAMMED M R, ALGHAMDI R A, et al. Urolithin A and B alter cellular metabolism and induce metabolites associated with apoptosis in leukemic cells[J].Int J Mol Sci,2021,22(11): 5465.
|
8 |
BEJANYAN N, WEISDORF D J, LOGAN B R,et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study[J]. Biol Blood Marrow Transplant, 2015, 21(3): 454-459.
|
9 |
THOL F, SCHLENK R F, HEUSER M, et al. How I treat refractory and early relapsed acute myeloid leukemia[J]. Blood, 2015, 126(3): 319-327.
|
10 |
ZHONG W J, MA L D, YANG F F, et al. Matrine, a potential c-Myc inhibitor, suppresses ribosome biogenesis and nucleotide metabolism in myeloid leukemia[J]. Front Pharmacol, 2022, 13: 1027441.
|
11 |
JIN H, ZHANG Y, YU S J, et al. Venetoclax combined with azacitidine and homoharringtonine in relapsed/refractory AML: a multicenter, phase 2 trial[J]. J Hematol Oncol, 2023, 16(1): 42.
|
12 |
AL-HARBI S A, ABDULRAHMAN A O, ZAMZAMI M A, et al. Urolithins: the gut based polyphenol metabolites of ellagitannins in cancer prevention, a review[J]. Front Nutr, 2021, 8: 647582.
|
13 |
GANDHI G R, ANTONY P J, CEASAR S A, et al. Health functions and related molecular mechanisms of ellagitannin-derived urolithins[J]. Crit Rev Food Sci Nutr, 2024, 64(2): 280-310.
|
14 |
ROGOVSKII V S.The therapeutic potential of urolithin A for cancer treatment and prevention[J]. Curr Cancer Drug Targets, 2022, 22(9): 717-724.
|
15 |
GIMÉNEZ-BASTIDA J A, ÁVILA-GÁLVEZ M, ESPÍN J C,et al. The gut microbiota metabolite urolithin A, but not other relevant urolithins, induces p53-dependent cellular senescence in human colon cancer cells [J]. Food Chem Toxicol, 2020, 139: 111260.
|
16 |
NORDEN E, HEISS E H. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells[J]. Carcinogenesis, 2019, 40(1): 93-101.
|
17 |
EL-WETIDY M S, AHMAD R, RADY I, et al. Urolithin A induces cell cycle arrest and apoptosis by inhibiting Bcl-2, increasing p53-p21 proteins and reactive oxygen species production in colorectal cancer cells[J]. Cell Stress Chaperones, 2021, 26(3): 473-493.
|
18 |
LV M Y, SHI C J, PAN F F, et al. Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/β-catenin signaling[J]. J Cell Biochem, 2019, 120(10): 17273-17282.
|
19 |
EIDIZADE F, SOUKHTANLOO M, ZHIANI R,et al. Inhibition of glioblastoma proliferation, invasion, and migration by Urolithin Bthrough inducing G0/G1 arrest and targeting MMP-2 /-9 expression and activity[J]. Biofactors, 2023, 49(2): 379-389.
|
20 |
RAHIMI-KALATEH SHAH MOHAMMAD G, MOTAVALIZADEHKAKHKY A, DARROUDI M, et al. Urolithin B loaded in cerium oxide nanoparticles enhances the anti-glioblastoma effects of free urolithin B in vitro [J]. J Trace Elem Med Biol, 2023, 78: 127186.
|
21 |
TOTIGER T M, SRINIVASAN S, JALA V R, et al. Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer[J]. Mol Cancer Ther, 2019, 18(2): 301-311.
|
22 |
ZHANG Y J, JIANG L, SU P F, et al. Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway[J]. Drug Dev Res, 2023, 84(2): 172-184.
|
23 |
TOUBAL S, OIRY C, BAYLE M, et al. Urolithin C increases glucose-induced ERK activation which contributes to insulin secretion[J]. Fundam Clin Pharmacol, 2020, 34(5): 571-580.
|
24 |
XU J Y, TIAN H Y, JI Y J, et al. Urolithin C reveals anti-NAFLD potential via AMPK-ferroptosis axis and modulating gut microbiota[J]. Naunyn Schmiedebergs Arch Pharmacol, 2023, 396(10): 2687-2699.
|
25 |
HSU C C, PENG D N, CAI Z, et al. AMPK signaling and its targeting in cancer progression and treatment[J]. Semin Cancer Biol, 2022, 85: 52-68.
|
26 |
PENG B, ZHANG S Y, CHAN K I, et al. Novel anti-cancer products targeting AMPK: natural herbal medicine against breast cancer[J].Molecules,2023,28(2): 740.
|
27 |
WANG S Y, LI H Y, YUAN M H, et al. Role of AMPK in autophagy[J]. Front Physiol, 2022, 13: 1015500.
|